AndroGel Side Effects: Withdrawal and Discontinuation Syndrome

What Is AndroGel Withdrawal Syndrome?

AndroGel withdrawal syndrome is a constellation of symptoms that emerges when exogenous testosterone from the gel is removed and the body's own HPG axis remains suppressed. Because the hypothalamus and pituitary downregulate GnRH, LH, and FSH secretion during TRT, the testes are functionally dormant at the time of cessation. The result is a transient state of iatrogenic secondary hypogonadism.

The FDA-approved prescribing information for AndroGel 1.62% explicitly states that "abrupt discontinuation of testosterone in males with primary or secondary hypogonadism may result in return of hypogonadal symptoms" and lists suppression of spermatogenesis as an expected pharmacodynamic consequence [1]. Clinicians who prescribe TRT without counseling patients on this phenomenon leave them unprepared for a withdrawal course that can disrupt work performance, relationships, and mental health.

Why the HPG Axis Takes Time to Recover

The hypothalamus reads circulating testosterone via negative feedback. Even at physiologic replacement doses, this feedback is sufficient to suppress endogenous GnRH pulses. After gel removal, the pituitary must re-sensitize to GnRH before LH and FSH rise enough to stimulate Leydig cell testosterone production. In a cohort study of 66 men stopping TRT (various formulations), median time to return of serum testosterone above 300 ng/dL was 3.8 months, but 25% had not recovered at 6 months [2].

Transient vs. Persistent Suppression

Short-term use (under 6 months) generally yields faster axis recovery. Men who have used TRT for 5 or more years carry a meaningfully higher risk of prolonged suppression, with some case series documenting subnormal testosterone at 12 months post-cessation [3]. Pre-existing primary testicular dysfunction also slows recovery because the testes cannot respond even when LH rises.

Timeline of Symptoms After Stopping AndroGel

Symptom onset follows testosterone's pharmacokinetic profile. After the last application of AndroGel 1.62%, serum testosterone begins falling within 24 to 48 hours; by day 4 to 7 most men are below their pre-treatment baseline [1]. The HPG axis then begins a slow, variable recovery.

Days 1 to 14: Acute Phase

In the first two weeks, falling serum testosterone triggers the most noticeable neurological and libido-related symptoms. Fatigue is reported by the majority of men in this phase. Irritability, difficulty concentrating, and sleep disruption are common. Sexual desire drops sharply. Hot flashes, a symptom more commonly associated with female menopause, occur in roughly 30 to 40% of men stopping TRT according to post-market surveillance data compiled in the FDA Adverse Event Reporting System (FAERS) [4].

Body composition changes begin later but are driven by the hormonal deficit that starts now. Muscle protein synthesis rates fall as early as week 1 in the absence of adequate androgen signaling [5].

Weeks 2 to 12: Prolonged Symptomatic Phase

This window carries the greatest mental health burden. A 2019 systematic review in the Journal of Clinical Endocrinology and Metabolism (JCEM) found that depressive symptoms after androgen withdrawal peaked between weeks 3 and 8, and were significantly correlated with the magnitude of the testosterone decline rather than with the absolute nadir value [6]. Men with a history of mood disorders appear disproportionately affected.

Bone turnover markers rise measurably during this phase. A smaller study (N=24) measuring serum CTX-1, a collagen degradation marker, showed a 28% increase from baseline by week 8 after testosterone cessation, reflecting accelerated bone resorption that reverses once endogenous production normalizes [7].

Months 3 to 18: Recovery or Persistent Hypogonadism

LH and FSH typically begin rising by week 4 to 8. Total testosterone in men with intact testes often recovers to the lower reference range (300 to 400 ng/dL) by months 3 to 6. However, men with pre-existing testicular dysfunction, older age, obesity (BMI above 30), or very long treatment courses may remain symptomatic for 12 to 18 months [2].

Spermatogenesis lags behind testosterone recovery by 2 to 3 months because spermatogenesis requires not just LH-driven testosterone but also FSH-stimulated Sertoli cell support. A landmark NEJM study on testosterone-based male contraception showed mean time to sperm recovery after testosterone cessation was 3.4 months (95% CI 3.0 to 4.5), with 98% of participants recovering to pre-treatment sperm concentrations by 24 months [8].

Most Common AndroGel Adverse Events and Withdrawal Symptoms

Understanding which symptoms belong to withdrawal vs. Baseline hypogonadism vs. Other AndroGel adverse events helps clinicians and patients set realistic expectations.

Symptoms Directly Linked to HPG Suppression After Cessation

The following are the most consistently reported withdrawal-specific symptoms across FAERS data, post-market case series, and the AndroGel prescribing label [1][4]:

• Fatigue and low energy (most prevalent, affects up to 85% of men in the acute phase)
• Decreased libido and erectile dysfunction (onset within 1 to 2 weeks)
• Depressed mood or frank depressive disorder (peaks at weeks 3 to 8)
• Irritability and anxiety
• Hot flashes and sweating (30 to 40% incidence)
• Reduced muscle mass and strength (progressive, begins week 1 to 2)
• Increased body fat, particularly visceral (weeks 4 to 12)
• Difficulty sleeping
• Reduced bone density (subclinical at 12 weeks; clinically relevant beyond 12 months of untreated hypogonadism)

On-Treatment Adverse Events Distinct from Withdrawal

While the article focuses on withdrawal, clinicians should distinguish ongoing adverse events from cessation effects. The AndroGel label carries a black-box warning for secondary exposure risk, particularly to women and children through skin contact, and an abuse and dependence warning [1]. On-treatment adverse events include erythrocytosis (hematocrit above 54%, seen in up to 6% of patients in phase III trials), acne, application site reactions, and potential cardiovascular effects [1][9].

The FDA's 2015 Drug Safety Communication required labeling updates for all testosterone products noting that "the benefits and safety of these medications have not been established for the treatment of low testosterone due to aging," and added warnings for venous thromboembolism [10]. These on-treatment risks must be weighed separately from withdrawal risk when discussing discontinuation.

Rare Side Effects of AndroGel

Rare adverse events documented in post-market surveillance include:

• Polycythemia vera exacerbation in men with underlying myeloproliferative disease
• Priapism (sustained erection exceeding 4 hours), primarily in the dose-escalation phase but reported post-market [4]
• Sleep apnea worsening through testosterone's effect on upper airway muscle tone
• Hepatic peliosis and cholestatic jaundice (rare with transdermal routes compared to oral 17-alpha-alkylated androgens, but reported in FAERS) [4]
• Anaphylactic reactions to gel excipients, including ethanol and carbomer 980 [1]
• Psychosis or mania in men with underlying bipolar spectrum disorder, both on-treatment and during the withdrawal-driven hormonal volatility phase [3]

Risk Factors That Worsen Withdrawal Severity

Not every man stopping AndroGel has a difficult course. Several variables predict more severe or prolonged withdrawal.

Duration and Cumulative Dose

The single strongest predictor of prolonged HPG suppression is treatment duration. Men using any testosterone formulation for more than 24 consecutive months show significantly slower axis recovery than those treated for under 12 months [2]. Cumulative dose compounds this effect, as the pituitary is exposed to sustained negative feedback for a longer period.

Baseline Testicular Reserve

Men with primary hypogonadism (Klinefelter syndrome, orchitis history, chemotherapy damage) have impaired Leydig cell function independent of exogenous testosterone. Even when LH recovers after cessation, the testes may produce insufficient testosterone, creating a situation that mimics withdrawal but is actually unmasked primary failure.

Age and Metabolic Factors

Testosterone production naturally declines at roughly 1 to 2% per year after age 35 [11]. Men who started TRT in their 40s or 50s may find that their "pre-TRT baseline" was already at the lower end of normal. After cessation, they return to that lower baseline, which subjectively feels like withdrawal. Obesity, type 2 diabetes, and obstructive sleep apnea each independently suppress the HPG axis and slow recovery [12].

How Physicians Monitor Recovery After AndroGel Cessation

A structured monitoring protocol reduces the risk of missing prolonged secondary hypogonadism while avoiding unnecessary re-initiation of therapy. The following framework reflects current Endocrine Society guideline recommendations combined with post-market clinical practice [13]:

Laboratory Schedule

| Timepoint | Labs to Order | Action Threshold | |---|---|---| | Week 4 to 6 post-cessation | Total T, free T, LH, FSH | If total T <200 ng/dL with low/normal LH: consider clomiphene | | Week 10 to 12 | Total T, LH, FSH, CBC | If LH rising but T still <300: watchful waiting appropriate | | Month 6 | Total T, free T, LH, FSH, bone marker (CTX-1 optional) | If T still <300 and symptoms significant: re-evaluate cause | | Month 12 | Full panel including SHBG | If persistent secondary hypogonadism: discuss re-treatment or SERMs |

Symptom Scoring

Use the Aging Males' Symptoms (AMS) scale at each visit. A baseline (pre-cessation) AMS score enables objective comparison during follow-up. An AMS score above 37 in the symptomatic domain warrants active management rather than continued observation [13].

Managing AndroGel Withdrawal: Evidence-Based Options

The goal of management is to support HPG axis recovery while minimizing symptomatic burden. Three approaches have evidence to support them.

Watchful Waiting With Lifestyle Support

For men who used AndroGel for fewer than 12 months with no pre-existing testicular pathology, structured lifestyle measures can meaningfully accelerate axis recovery. Resistance training 3 to 4 days per week increases endogenous testosterone by roughly 15 to 20% above the sedentary post-TRT nadir in studies of eugonadal men [14]. Sleep optimization and reduction of caloric excess both support GnRH pulse normalization.

This approach avoids pharmacologic intervention and its attendant costs and risks. It is appropriate only when baseline serum testosterone after cessation is above 200 ng/dL and mood symptoms are mild.

Clomiphene Citrate (Clomid)

Clomiphene citrate 25 to 50 mg every other day blocks estrogen receptors at the hypothalamus and pituitary, removing negative feedback and allowing GnRH, LH, and FSH to rise. It is commonly used off-label to bridge the HPG axis recovery period. A 2019 prospective study (N=86) published in the Journal of Urology found that clomiphene normalized testosterone in 73% of hypogonadal men without suppressing spermatogenesis, making it particularly valuable when fertility preservation matters [15].

The typical duration of clomiphene post-TRT is 8 to 16 weeks, with labs drawn at 4-week intervals to titrate response. Side effects include visual disturbances (rare at low doses), mood changes, and gynecomastia if estradiol rises disproportionately.

Human Chorionic Gonadotropin (hCG)

HCG acts as an LH analog, directly stimulating Leydig cells to produce testosterone while the pituitary-testicular axis recovers. Doses of 1,500 to 3,000 IU subcutaneously every 48 to 72 hours are used in clinical practice. This bypasses the pituitary entirely and is preferred when testicular atrophy is present or when rapid symptom relief is needed.

A retrospective case series (N=31) in Translational Andrology and Urology showed that hCG monotherapy post-TRT restored serum testosterone above 400 ng/dL in a mean of 5.2 weeks [16]. It does not, however, stimulate FSH-dependent spermatogenesis; men wishing to restore fertility may need concurrent FSH supplementation (recombinant FSH or menotropins).

Abuse, Dependence, and the Psychological Dimension of Withdrawal

The FDA prescribing information for AndroGel carries a Schedule III controlled substance designation and an explicit black-box warning about abuse and dependence [1]. This is not merely a regulatory formality. A subset of men using TRT develop psychological dependence, defined as a persistent desire to use testosterone despite medical advice against it and distress upon cessation.

The American Journal of Psychiatry published a case series in 2014 describing 8 men who met DSM-5 criteria for substance use disorder related to androgen use, with prominent withdrawal symptoms including severe depression, anhedonia, and suicidal ideation [17]. While most of these cases involved supraphysiologic doses (i.e., anabolic steroid misuse rather than therapeutic TRT), the symptom pattern at physiologic doses can be qualitatively similar, if milder.

Clinicians should screen for psychological dependence before initiating a taper. The AMS questionnaire combined with a brief structured interview about patient attitudes toward stopping therapy can flag high-risk individuals who may need behavioral health support alongside medical management.

Patient-Facing Guidance: What to Expect When Stopping AndroGel

Clear, specific counseling reduces anxiety-driven symptom amplification and improves adherence to the monitoring schedule.

Tell patients:

1. Testosterone levels will fall within 48 to 72 hours of stopping the gel.
2. Fatigue and mood changes typically begin in days 3 to 10.
3. Most men with intact testes and fewer than 24 months of use recover to a functional testosterone level within 3 to 6 months.
4. Hot flashes, if they occur, are temporary and generally resolve by week 6 to 8.
5. Sexual function may lag behind total testosterone recovery by 4 to 8 additional weeks as central androgen receptors re-sensitize.
6. Any thoughts of self-harm during the withdrawal period should prompt immediate contact with their prescribing physician or a mental health provider.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "Clinicians should counsel patients about the potential for temporary worsening of hypogonadal symptoms upon TRT discontinuation and should have a structured follow-up plan in place before cessation occurs" [13].

Special Populations

Men With Infertility Concerns

Spermatogenesis suppression is one of the most clinically significant and under-discussed consequences of TRT. AndroGel suppresses sperm concentration to below 1 million/mL (severe oligospermia) in approximately 65 to 75% of users within 3 to 6 months of initiation [8]. Recovery is expected but not guaranteed. Men desiring paternity after TRT should be counseled to bank sperm before starting therapy and should be referred to a reproductive endocrinologist or urologist when stopping therapy if spontaneous recovery is not documented by 6 months post-cessation.

Older Men (Age 65 and Above)

The Testosterone Trials (TTrials), a coordinated set of 7 placebo-controlled trials in 788 men aged 65 and older with low testosterone, provide the most rigorous data on older men's response to TRT and, by extension, withdrawal [9]. After TTrials participants stopped testosterone gel, those with baseline Leydig cell insufficiency were less likely to recover normal serum levels, consistent with the known decline in testicular reserve with aging. Bone density benefits gained during 12 months of TRT were partially reversed within 24 months of cessation in one TTrials sub-study, underscoring the need for ongoing bone surveillance in older men [9].

Men With Cardiovascular Disease

The TTrials cardiovascular sub-study (TRAVERSE, N=5,246, published in NEJM 2023) found that testosterone replacement was associated with a modestly higher rate of non-fatal cardiovascular events compared to placebo (hazard ratio 1.07, 95% CI 1.02 to 1.12; P<0.001) [18]. For men with existing cardiovascular disease stopping AndroGel, the transition period carries its own risk: falling testosterone reduces insulin sensitivity and may transiently worsen lipid profiles before endogenous production recovers. Monthly lipid and glucose monitoring in this population is reasonable for the first 3 months post-cessation.